MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. ITGR
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Integer Holdings (ITGR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Integer Holdings
NYSE•Healthcare•Medical Devices
$126.54-0.02(<0.01%)After hours
Market Cap
$4.31B
P/E
41.5x
P/S
2.4x
P/B
2.5x

Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

B

How this company scores

GoodMetricSide Score: 60/100

Strongest: Growth (18/25); weakest: Cash & Earnings Quality (14/25).

Profitability14/25
Growth18/25
Balance Sheet & Red Flags14/25
Cash & Earnings Quality14/25
Strengths
Rising earningsConsistent free cash flowProfit converts from growthConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 41.5x5y range 21.0x – 51.8x
P/E 41.5x · near its 20-quarter median

Currently near its 20-quarter median.

P/S · 2.4x5y range 1.5x – 2.6x
P/S 2.4x · near its 20-quarter median

Currently near its 20-quarter median.

P/B · 2.5x5y range 1.5x – 2.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 32.6% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Price & Volume
Market Cap $4.31B

Metrics at a Glance

as of October 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$1.83B
2Q
Q. Revenue
$449.66M
4%
TTM EBITDA
$289.95M
3Q
TTM Op. Income
$150.54M
3Q
Q. Op. Income
$28.21M
50%
TTM Net Income
$103.70M
2Q
Q. Net Income
$14.98M
62%
EPS
$0.44
61%
Shares Out.
$34.03M
3%
$1.83B in TTM revenue grew 0.5% YoY, reaching $449.66M last quarter. TTM EBITDA of $289.95M and TTM operating income of $150.54M show growth is flowing through to the bottom line. TTM net income of $103.70M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
22.6%
6Q
EBITDA Margin
13.9%
3Q
Op. Margin
6.3%
48%
Net Margin
3.3%
61%
Op. margin of 6.3% is down 5.8% YoY — costs are rising relative to revenue. Net margin at 3.3% and gross margin of 22.6% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 48% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
41.5x
2Q
P/S Ratio
2.4x
3Q
P/B Ratio
2.5x
3Q
At 41.5x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 2.4x and P/B of 2.5x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Across the last 8 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$3.39B
0%
Cash
$14.13M
76%
Long-Term Debt
$1.22B
2Q
Book Value
$1.73B
2Q
D/E Ratio
0.7
2Q
Debt/EBITDA
19.5
46%
With $3.39B in assets and $1.22B in long-term debt, D/E is 0.7and book value is $1.73B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$36.63M
44%
TTM Free Cash Flow
$81.82M
33%
FCF Margin
4.5%
33%
FCF / Net Income
0.8
43%
TTM FCF of $81.82M on $36.63M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 33% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 2.5x
· near its 20-quarter median

Currently near its 20-quarter median.